Phase I results demonstrate highly differentiated safety and PK profile of ADG126, a masked anti-CTLA-4 SAFEbody in patients with advanced solid tumors

Ipilimumab (Ipi), the only approved anti-CTLA-4 mAb, is associated with severe AEs in >20% of Pts as monotherapy at 3 mg/kg (mpk), and 1 mpk is used in combination with nivolumab to mitigate safety concerns. ADG126 SAFEbody applies precision masking peptide to the anti-CTLA-4 ADG116 NEObody™ for 6-fold greater safety over ADG116, and has an improved safety and efficacy profile over Ipi. ADG126 targets a unique epitope of CTLA-4, inducing strong ADCC-mediated Treg depletion and CD8+ Teff cells in the tumor microenvironment (TME) to limit on-target AEs in normal tissues.